AR058739A1 - Composicion para la erradicacion de helicobacter pylori y su uso - Google Patents
Composicion para la erradicacion de helicobacter pylori y su usoInfo
- Publication number
- AR058739A1 AR058739A1 ARP060105782A ARP060105782A AR058739A1 AR 058739 A1 AR058739 A1 AR 058739A1 AR P060105782 A ARP060105782 A AR P060105782A AR P060105782 A ARP060105782 A AR P060105782A AR 058739 A1 AR058739 A1 AR 058739A1
- Authority
- AR
- Argentina
- Prior art keywords
- proton pump
- pump inhibitor
- clarithromycin
- amoxicillin
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 241000590002 Helicobacter pylori Species 0.000 title abstract 3
- 230000008029 eradication Effects 0.000 title abstract 3
- 229940037467 helicobacter pylori Drugs 0.000 title abstract 3
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 6
- 239000000612 proton pump inhibitor Substances 0.000 abstract 6
- -1 clarithromycin compound Chemical class 0.000 abstract 5
- 229960002626 clarithromycin Drugs 0.000 abstract 4
- 239000010410 layer Substances 0.000 abstract 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical class C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 abstract 2
- 229960003022 amoxicillin Drugs 0.000 abstract 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 2
- 239000011247 coating layer Substances 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 abstract 2
- 238000007789 sealing Methods 0.000 abstract 2
- 241000589989 Helicobacter Species 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012055 enteric layer Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960000381 omeprazole Drugs 0.000 abstract 1
- 229920000193 polymethacrylate Polymers 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 239000011241 protective layer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion para la erradicacion del helicobacter pylori de granulado para la administracion oral que comprende simultáneamente un inhibidor de la bomba de protones, un compuesto de claritromicina y un compuesto de amoxicilina. Dichas composiciones son adecuadas para llenarse en sobres y son utiles en el tratamiento de trastornos asociados con la bacteria Helicobacter. Reivindicacion 1: Una composicion para la erradicacion de Helicobacter pylori de granulado para administracion oral para quesea llenada en sobres que comprende: a) de 5 a 40 mg de u inhibidor de la bomba de protones por sobre; b) de 50 a 1000 mg de un compuesto de claritromicina por sobre; y c) de 100 a 200 mg de u compuesto de amoxicilina por sobre, caracterizada porque el granulado comprende: (i) un nucleo que comprende el inhibidor de la bomba de protones, preparado bien mediante revestimiento con un inhibidor de la bomba de protones de un nucleo inerte, o elaborando un nucleo mixto esferonizado que contiene el inhibidor de la bomba de protones; (ii) una capa protectora; (iii) una capa entérica de polimetacrilato; (iv) una capa de sellado protectora opcional; (v) a) una capa de revestimiento estabilizada frente al pH que comprende una mezcla de los compuestos de claritromicina y amoxicilina; o b) dos capas de revestimiento estabilizadas frente al pH que comprenden cada una los compuestos de claritromicina y amoxicilina independientemente, separadas por otra capa de sellado si fuera necesario; y (vi) una capa externa final para proteger y mejorar el sabor de la formulacion. Reivindicacion 5: La composicion de acuerdo con la reivindicacion 4, caracterizada porque el inhibidor de la bomba de protones es un compuesto de omeprazol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100029A EP1803450A1 (en) | 2006-01-03 | 2006-01-03 | Pharmaceutical compositions for the eradication of helicobacter pylori |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058739A1 true AR058739A1 (es) | 2008-02-20 |
Family
ID=36587265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105782A AR058739A1 (es) | 2006-01-03 | 2006-12-26 | Composicion para la erradicacion de helicobacter pylori y su uso |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1803450A1 (es) |
| AR (1) | AR058739A1 (es) |
| PE (1) | PE20071174A1 (es) |
| TW (1) | TW200744676A (es) |
| UY (1) | UY30065A1 (es) |
| WO (1) | WO2007077158A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090253808A1 (en) * | 2007-11-12 | 2009-10-08 | Pharmaceutics International, Inc. | Tri-molecular complexes and their use in drug delivery systems |
| RU2403904C1 (ru) * | 2009-02-26 | 2010-11-20 | Федеральное государственное учреждение "Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Росздрава" | Способ профилактики острых гастродуоденальных язв у больных колоректальным раком в раннем послеоперационном периоде |
| IT1400415B1 (it) | 2010-05-26 | 2013-05-31 | Over S R L | Composizioni per il trattamento della infezione da helicobacter pylori. |
| CA2900763C (en) | 2013-02-13 | 2021-04-06 | Reza Fathi | Pharmaceutical compositions for the treatment of helicobacter pylori |
| BR202014031413U2 (pt) * | 2014-12-15 | 2016-06-21 | Ems Sa | kit para administração conjunta de medicamentos |
| CN104940170A (zh) * | 2015-07-23 | 2015-09-30 | 浙江亚太药业股份有限公司 | 一种埃索美拉唑镁肠溶胶囊及其制备方法 |
| US11878011B2 (en) | 2020-05-07 | 2024-01-23 | Redhill Biopharma Ltd. | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9500422D0 (sv) | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| US6132768A (en) | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
| US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| SI9700186B (sl) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6576625B2 (en) | 2001-03-16 | 2003-06-10 | Panacea Biotic Limited | Targeted vesicular constructs for cytoprotection and treatment of H. pylori infections |
| CA2481271A1 (en) | 2002-04-03 | 2003-10-09 | Ranbaxy Laboratories Limited | Clarithromycin formulations having improved bioavailability |
| BR0308990A (pt) | 2002-04-03 | 2005-01-04 | Ranbaxy Lab Ltd | Composição farmacêutica de eritromicina e seus derivados com sabor mascarado e processo de sua preparação |
| US20040180935A1 (en) | 2003-02-28 | 2004-09-16 | Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Inc. | Crystalline form Z of rabeprazole sodium and process for preparation thereof |
| KR100581967B1 (ko) * | 2003-12-18 | 2006-05-22 | 한국유나이티드제약 주식회사 | 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법 |
| WO2005082331A2 (en) | 2004-02-26 | 2005-09-09 | Ranbaxy Laboratories Limited | Extended release tablets of clarithromycin |
-
2006
- 2006-01-03 EP EP06100029A patent/EP1803450A1/en not_active Withdrawn
- 2006-12-21 WO PCT/EP2006/070129 patent/WO2007077158A1/en not_active Ceased
- 2006-12-22 PE PE2006001688A patent/PE20071174A1/es not_active Application Discontinuation
- 2006-12-26 AR ARP060105782A patent/AR058739A1/es not_active Application Discontinuation
- 2006-12-26 UY UY30065A patent/UY30065A1/es unknown
- 2006-12-27 TW TW095149152A patent/TW200744676A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007077158A1 (en) | 2007-07-12 |
| PE20071174A1 (es) | 2007-11-23 |
| EP1803450A1 (en) | 2007-07-04 |
| UY30065A1 (es) | 2007-04-30 |
| TW200744676A (en) | 2007-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100473A2 (es) | Un método para la manufactura de una preparación para administración oral | |
| EE05405B1 (et) | Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid | |
| MX2010003923A (es) | Formulacion farmaceutica de valsartan. | |
| BRPI0418228A (pt) | forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil | |
| WO2008063910A3 (en) | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions | |
| WO2011030351A3 (en) | Taste - masked pharmaceutical compositions | |
| WO2007143652A3 (en) | Chewable soft gelatin capsules | |
| ATE375797T1 (de) | Pharmazeutische zubereitungen gegen kopfschmerz, migräne, nausea und erbrechen | |
| WO2005009370A3 (en) | Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | |
| BR112014003061A2 (pt) | composição farmacêutica com sabor mascarado | |
| AR033859A1 (es) | Inhibidores de la metaloproteinasa de la matriz | |
| NO20014102L (no) | Nye tricykliske forbindelser og deres anvendelse innenfor medisin, fremgangsmåte for deres fremstilling og farmasöytisksammensetning som inneholder dem | |
| BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
| CY1106542T1 (el) | Μεθοδος για παρασκευη φαρμακευτικων συνθεσεων για χρηση με συνταγοποιησεις μαλακης ζελατινης | |
| BR0212258A (pt) | Combinações anti-câncer | |
| AR061169A1 (es) | Formulaciones farmaceuticas de fenilferina y composiciones para su absorcion en el colon | |
| NO20083605L (no) | Stable oral pharmaceutical composition containing thyroid hormone receptor agonists | |
| EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
| AR058739A1 (es) | Composicion para la erradicacion de helicobacter pylori y su uso | |
| BRPI0418765A (pt) | composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástese de células tumorais, método de tratar carcinomas, método de tratar uma doença pró-droga, método de inibir trombose | |
| WO2007097989A3 (en) | A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer | |
| NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
| DK2053929T3 (da) | Resin-indkapslet højintensivt sødemiddel | |
| WO2007131070A3 (en) | Compositions, dosage forms and methods of treating emesis | |
| WO2010046933A3 (en) | Pharmaceutical compositions of taste-masked linezolid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |